阿尔茨海默病中的tau蛋白聚集：磷酸化起什么作用？
Tau aggregation in Alzheimer's disease: what role for phosphorylation?
作者信息
Lippens Guy, Sillen Alain, Landrieu Isabelle, Amniai Laziza, Sibille Nathalie, Barbier Pascale, Leroy Arnaud, Hanoulle Xavier, Wieruszeski Jean-Michel
机构信息
CNRS UMR 8576, Unité de Glycobiologie Structurale et Fonctionnelle, Université des Sciences et Technologies de Lille 1, Villeneuve d'Ascq, France.
出版信息
Prion. 2007 Jan-Mar;1(1):21-5. doi: 10.4161/pri.1.1.4055. Epub 2007 Jan 23.
Abstract
The crucial role of the neuronal Tau protein in microtubule stabilization and axonal transport suggests that too little or too much Tau might lead to neuronal dysfunction. The presence of a hyper phosphorylated but non aggregated molecule as a toxic species that might sequester normal Tau is discussed. We present recent in vitro results that might allow us to dissect the role of individual phosphorylation sites on its structure and function. We also discuss in this review the role of phosphorylation for the aggregation of the neuronal Tau protein, and compare it to the aggregation induced by external poly anions.
摘要
神经元 Tau 蛋白在微管稳定和轴突运输中的关键作用表明，Tau 蛋白过少或过多都可能导致神经元功能障碍。本文讨论了一种过度磷酸化但未聚集的分子作为可能隔离正常 Tau 的毒性物质的存在。我们展示了最近的体外实验结果，这些结果可能使我们能够剖析单个磷酸化位点在其结构和功能上的作用。在这篇综述中，我们还讨论了磷酸化在神经元 Tau 蛋白聚集中的作用，并将其与外部多阴离子诱导的聚集进行比较。
相似文献
1
Tau aggregation in Alzheimer's disease: what role for phosphorylation?
Prion. 2007 Jan-Mar;1(1):21-5. doi: 10.4161/pri.1.1.4055. Epub 2007 Jan 23.
2
Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.
Biochemistry. 1999 Mar 23;38(12):3549-58. doi: 10.1021/bi981874p.
3
Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease.
Mol Neurobiol. 1991;5(2-4):399-410. doi: 10.1007/BF02935561.
4
Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules.
Neurosci Lett. 2001 Oct 26;312(3):141-4. doi: 10.1016/s0304-3940(01)02206-6.
5
Tau phosphorylation and aggregation in Alzheimer's disease pathology.
FEBS Lett. 2006 May 22;580(12):2922-7. doi: 10.1016/j.febslet.2006.02.067. Epub 2006 Mar 3.
6
Lost after translation: missorting of Tau protein and consequences for Alzheimer disease.
Trends Neurosci. 2014 Dec;37(12):721-32. doi: 10.1016/j.tins.2014.08.004. Epub 2014 Sep 12.
7
Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.
Biochem J. 1997 May 1;323 ( Pt 3)(Pt 3):577-91. doi: 10.1042/bj3230577.
8
Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease.
J Neurosci. 2012 Feb 15;32(7):2430-41. doi: 10.1523/JNEUROSCI.5927-11.2012.
9
The role of tau phosphorylation in the pathogenesis of Alzheimer's disease.
Curr Alzheimer Res. 2006 Dec;3(5):449-63. doi: 10.2174/156720506779025279.
10
Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses.
Neurobiol Aging. 2003 Dec;24(8):1079-85. doi: 10.1016/j.neurobiolaging.2003.04.007.
引用本文的文献
1
The reverse transcriptase inhibitor 3TC modulates hippocampal transcriptome signatures of inflammation in tauopathy model mice.
Exp Gerontol. 2024 Jul;192:112458. doi: 10.1016/j.exger.2024.112458. Epub 2024 May 21.
2
Development of an accelerated cellular model for early changes in Alzheimer's disease.
Sci Rep. 2023 Oct 26;13(1):18384. doi: 10.1038/s41598-023-45826-5.
3
Big versus small: The impact of aggregate size in disease.
Protein Sci. 2023 Jul;32(7):e4686. doi: 10.1002/pro.4686.
4
Regulation of Biomolecular Condensates by Poly(ADP-ribose).
Chem Rev. 2023 Jul 26;123(14):9065-9093. doi: 10.1021/acs.chemrev.2c00851. Epub 2023 Apr 28.
5
Effects of Current Psychotropic Drugs on Inflammation and Immune System.
Adv Exp Med Biol. 2023;1411:407-434. doi: 10.1007/978-981-19-7376-5_18.
6
Anti-Amyloidogenic Effects of Fruits and Its Active Constituents.
Molecules. 2023 Jan 19;28(3):1017. doi: 10.3390/molecules28031017.
7
Reducing PDK1/Akt Activity: An Effective Therapeutic Target in the Treatment of Alzheimer's Disease.
Cells. 2022 May 24;11(11):1735. doi: 10.3390/cells11111735.
8
Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations.
RSC Adv. 2019 Dec 24;10(1):215-227. doi: 10.1039/c9ra09350h. eCollection 2019 Dec 20.
9
Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer's Disease and Diabetes.
Biomedicines. 2021 May 19;9(5):576. doi: 10.3390/biomedicines9050576.
10
Resolution-Based Therapies: The Potential of Lipoxins to Treat Human Diseases.
Front Immunol. 2021 Apr 23;12:658840. doi: 10.3389/fimmu.2021.658840. eCollection 2021.
本文引用的文献
1
NMR investigation of the interaction between the neuronal protein tau and the microtubules.
Biochemistry. 2007 Mar 20;46(11):3055-64. doi: 10.1021/bi061920i. Epub 2007 Feb 21.
2
The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism.
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):403-9. doi: 10.1073/pnas.0608332104. Epub 2006 Dec 29.
3
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.
Nat Cell Biol. 2007 Feb;9(2):139-48. doi: 10.1038/ncb1528. Epub 2006 Dec 24.
4
Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy.
Biochemistry. 2006 Oct 17;45(41):12560-72. doi: 10.1021/bi060964o.
5
Extending top-down mass spectrometry to proteins with masses greater than 200 kilodaltons.
Science. 2006 Oct 6;314(5796):109-12. doi: 10.1126/science.1128868.
6
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.
Acta Neuropathol. 2006 Oct;112(4):389-404. doi: 10.1007/s00401-006-0127-z. Epub 2006 Aug 12.
7
Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
J Neurochem. 2006 Aug;98(4):993-1006. doi: 10.1111/j.1471-4159.2006.03955.x. Epub 2006 Jun 19.
8
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9673-8. doi: 10.1073/pnas.0602913103. Epub 2006 Jun 12.
9
Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8864-9. doi: 10.1073/pnas.0603214103. Epub 2006 May 30.
10
NMR analysis of a Tau phosphorylation pattern.
J Am Chem Soc. 2006 Mar 22;128(11):3575-83. doi: 10.1021/ja054656+.
Zotero 插件